| General Information | |
|---|---|
| ZINC ID | ZINC000040976584 |
| Molecular Weight (Da) | 488 |
| SMILES | CCc1c(C2=NC(=O)C3(CCCC3)N2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C24Cl3N4O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.338 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| LogP | 7.502 |
| Activity (Ki) in nM | 1380.384 |
| Polar Surface Area (PSA) | 59.28 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.062 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.29 |
| Ilogp | 4.36 |
| Xlogp3 | 6.57 |
| Wlogp | 5.49 |
| Mlogp | 5.01 |
| Silicos-it log p | 6.95 |
| Consensus log p | 5.68 |
| Esol log s | -7.13 |
| Esol solubility (mg/ml) | 0.0000359 |
| Esol solubility (mol/l) | 7.37E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.61 |
| Ali solubility (mg/ml) | 0.0000119 |
| Ali solubility (mol/l) | 2.43E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.82 |
| Silicos-it solubility (mg/ml) | 7.37E-08 |
| Silicos-it solubility (mol/l) | 1.51E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.61 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.18 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.073 |
| Logd | 5.165 |
| Logp | 6.351 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | 7.98E-06 |
| Ppb | 0.9703 |
| Vdss | 0.806 |
| Fu | 0.0285 |
| Cyp1a2-inh | 0.249 |
| Cyp1a2-sub | 0.834 |
| Cyp2c19-inh | 0.831 |
| Cyp2c19-sub | 0.517 |
| Cl | 1.898 |
| T12 | 0.032 |
| H-ht | 0.541 |
| Dili | 0.961 |
| Roa | 0.669 |
| Fdamdd | 0.912 |
| Skinsen | 0.064 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.755 |
| Bcf | 2.417 |
| Igc50 | 5.056 |
| Lc50 | 6.372 |
| Lc50dm | 5.591 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.903 |
| Nr-aromatase | 0.852 |
| Nr-er | 0.843 |
| Nr-er-lbd | 0.042 |
| Nr-ppar-gamma | 0.555 |
| Sr-are | 0.883 |
| Sr-atad5 | 0.342 |
| Sr-hse | 0.051 |
| Sr-mmp | 0.936 |
| Sr-p53 | 0.97 |
| Vol | 452.924 |
| Dense | 1.073 |
| Flex | 0.143 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 1 |
| Qed | 0.473 |
| Synth | 3.412 |
| Fsp3 | 0.292 |
| Mce-18 | 96.355 |
| Natural product-likeness | -0.937 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |